Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.56 |
| ▸ | NT5E | P21589 | 3/20 | 0.48 |
| ▸ | PDE2A | O00408 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27423745 | 0.84 | ADORA3 (0.54) | ADORA3NT5EPDE2ALMNATP53 | |
| SCHEMBL4157625 | 0.82 | ADORA2A (0.61) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL27428840 | 0.78 | SLC29A1 (0.53) | ADORA3SLC29A1ADORA1 | |
| SCHEMBL27425390 | 0.77 | SLC29A1 (0.62) | ADORA3SLC29A1ADORA1ADORA2AADORA2B | |
| SCHEMBL27427402 | 0.76 | SLC29A1 (0.58) | ADORA3SLC29A1 | |
| SCHEMBL14264202 | 0.73 | ADORA3 (0.76) | ADORA3LMNATP53ADORA1ADORA2A | |
| SCHEMBL27424596 | 0.73 | SLC29A1 (0.52) | ADORA3NT5ESLC29A1ADORA1 | |
| SCHEMBL27426560 | 0.73 | SLC29A1 (0.62) | ADORA3SLC29A1ADORA1ADORA2AADORA2B | |
| SCHEMBL27427694 | 0.73 | SLC29A1 (0.56) | ADORA3SLC29A1 | |
| SCHEMBL3877328 | 0.72 | ADORA3 (1.00) | ADORA3NT5EPDE2ALMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024134541-A1 | HETEROCYCLIC COMPOUNDS AS ENT INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2024-06-27 | — | — | WO | disclosed |